Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery
The development of novel theranostic agents with outstanding diagnostic and therapeutic performances is still strongly desired in the treatment of hepatocellular carcinoma (HCC). Here, a fucoidan-modified mesoporous polydopamine nanoparticle dual-loaded with gadolinium iron and doxorubicin (FMPDA/Gd...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087622000940 |
| _version_ | 1798006135329914880 |
|---|---|
| author | Gaofeng Shu Lin Shen Jiayi Ding Junchao Yu Xiaoxiao Chen Xiaoju Guo Enqi Qiao Yaning Chen Chenying Lu Zhongwei Zhao Yongzhong Du Minjiang Chen Jiansong Ji |
| author_facet | Gaofeng Shu Lin Shen Jiayi Ding Junchao Yu Xiaoxiao Chen Xiaoju Guo Enqi Qiao Yaning Chen Chenying Lu Zhongwei Zhao Yongzhong Du Minjiang Chen Jiansong Ji |
| author_sort | Gaofeng Shu |
| collection | DOAJ |
| description | The development of novel theranostic agents with outstanding diagnostic and therapeutic performances is still strongly desired in the treatment of hepatocellular carcinoma (HCC). Here, a fucoidan-modified mesoporous polydopamine nanoparticle dual-loaded with gadolinium iron and doxorubicin (FMPDA/Gd3+/DOX) was prepared as an effective theranostic agent for magnetic resonance imaging (MRI)-guided chemo-photothermal therapy of HCC. It was found that FMPDA/Gd3+/DOX had a high photothermal conversion efficiency of 33.4% and excellent T1−MRI performance with a longitudinal relaxivity (r1) value of 14.966 mM−1·s − 1. Moreover, the results suggested that FMPDA/Gd3+/DOX could effectively accumulate into the tumor foci by dual-targeting the tumor-infiltrated platelets and HCC cells, which resulted from the specific interaction between fucoidan and overexpressed p-selectin receptors. The excellent tumor-homing ability and MRI-guided chemo-photothermal therapy therefore endowed FMPDA/Gd3+/DOX with a strongest ability to inhibit tumor growth than the respective single treatment modality. Overall, our study demonstrated that FMPDA/Gd3+/DOX could be applied as a potential nanoplatform for safe and effective cancer theranostics |
| first_indexed | 2024-04-11T12:50:13Z |
| format | Article |
| id | doaj.art-eb714cba943c465fb0493ac43313fea1 |
| institution | Directory Open Access Journal |
| issn | 1818-0876 |
| language | English |
| last_indexed | 2024-04-11T12:50:13Z |
| publishDate | 2022-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-eb714cba943c465fb0493ac43313fea12022-12-22T04:23:14ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762022-11-01176908923Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug deliveryGaofeng Shu0Lin Shen1Jiayi Ding2Junchao Yu3Xiaoxiao Chen4Xiaoju Guo5Enqi Qiao6Yaning Chen7Chenying Lu8Zhongwei Zhao9Yongzhong Du10Minjiang Chen11Jiansong Ji12Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, ChinaKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, ChinaKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, ChinaDepartment of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaShaoxing University School of Medcine, Shaoxing 312000, ChinaDepartment of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaDepartment of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, ChinaInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Corresponding authors.Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Corresponding authors.Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China; Corresponding authors.The development of novel theranostic agents with outstanding diagnostic and therapeutic performances is still strongly desired in the treatment of hepatocellular carcinoma (HCC). Here, a fucoidan-modified mesoporous polydopamine nanoparticle dual-loaded with gadolinium iron and doxorubicin (FMPDA/Gd3+/DOX) was prepared as an effective theranostic agent for magnetic resonance imaging (MRI)-guided chemo-photothermal therapy of HCC. It was found that FMPDA/Gd3+/DOX had a high photothermal conversion efficiency of 33.4% and excellent T1−MRI performance with a longitudinal relaxivity (r1) value of 14.966 mM−1·s − 1. Moreover, the results suggested that FMPDA/Gd3+/DOX could effectively accumulate into the tumor foci by dual-targeting the tumor-infiltrated platelets and HCC cells, which resulted from the specific interaction between fucoidan and overexpressed p-selectin receptors. The excellent tumor-homing ability and MRI-guided chemo-photothermal therapy therefore endowed FMPDA/Gd3+/DOX with a strongest ability to inhibit tumor growth than the respective single treatment modality. Overall, our study demonstrated that FMPDA/Gd3+/DOX could be applied as a potential nanoplatform for safe and effective cancer theranosticshttp://www.sciencedirect.com/science/article/pii/S1818087622000940Mesoporous polydopamineFucoidanP-selectin targetPlatelets bridgeCancer theranostics |
| spellingShingle | Gaofeng Shu Lin Shen Jiayi Ding Junchao Yu Xiaoxiao Chen Xiaoju Guo Enqi Qiao Yaning Chen Chenying Lu Zhongwei Zhao Yongzhong Du Minjiang Chen Jiansong Ji Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery Asian Journal of Pharmaceutical Sciences Mesoporous polydopamine Fucoidan P-selectin target Platelets bridge Cancer theranostics |
| title | Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery |
| title_full | Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery |
| title_fullStr | Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery |
| title_full_unstemmed | Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery |
| title_short | Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery |
| title_sort | fucoidan based dual targeting mesoporous polydopamine for enhanced mri guided chemo photothermal therapy of hcc via p selectin mediated drug delivery |
| topic | Mesoporous polydopamine Fucoidan P-selectin target Platelets bridge Cancer theranostics |
| url | http://www.sciencedirect.com/science/article/pii/S1818087622000940 |
| work_keys_str_mv | AT gaofengshu fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT linshen fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT jiayiding fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT junchaoyu fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT xiaoxiaochen fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT xiaojuguo fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT enqiqiao fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT yaningchen fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT chenyinglu fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT zhongweizhao fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT yongzhongdu fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT minjiangchen fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery AT jiansongji fucoidanbaseddualtargetingmesoporouspolydopamineforenhancedmriguidedchemophotothermaltherapyofhccviapselectinmediateddrugdelivery |